Recent and long-lasting infections: The need for avidity testing in HIV-1 infected subjects

New Microbiologica

Volumn 35, Issue 4, 2012, Pages 407-414

  Re, Maria Carla ^a,b   Bon, Isabella ^a   Grandi, Nicole ^a   Miserocchi, Anna ^a   Morini, Silvia ^a   Clo, Alberto ^a   Furlini, Giuliano ^a   Gibellini, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Avidity test; HIV diagnosis; Recent and long lasting infections

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; BLOOD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; ITALY; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

ANTIBODY AFFINITY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; ITALY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869176095     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ANTINORI A., JOHNSON M., MORENO S., YAZDANPANAH Y. ROCKSTROH J.K. (2010). Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir. Ther. 1, 31-35.
2. ANTINORI A., MARCOTULLIO S., AMMASSARI A., ANDREONI M., ANGARANO G., ARMIGNACCO O., CAROSI G., CINQUE P., D'ARMINIO MONFORTE A., DI PERRI G., ENSOLI B., FLORIDIA M., GALLI M., MASTROIANNI C., MATTEELLI A., MAZZOTTA F., MORONI M., PAL G., PUOTI M., PURO V., RIZZARDINI G., SAGNELLI E., VELLA S., VULLO V., LAZZARIN A; ITALIAN HIV GUIDELINES WORKING GROUP. (2012). Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 35, 113-159.
3. CAMPSMITH ML., RHODES PH., HALL HI., GREEN TA. (2010). Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J. Acquir. Immune Defic. Syndr. 53, 619-624.
4. CENTERS FOR DISEASE CONTROL AND PREVENTION. (1989). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb. Mortal. Wkly. Rep. 38, 1-7.
5. CENTERS FOR DISEASE CONTROL AND PREVENTION. (2003). Advancing HIV prevention: new strategies for a changing epidemic - United States. MMWR Morb. Mortal. Wkly. Rep. 52, 329-332.
6. CICCOZZI M., BON I., CIOTTI M. (2010) Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? New Microbiol. 33, 179-181.
7. COHEN M.S., GAY C.L., BUSCH M.P., HECHT F.M. (2010). The detection of acute HIV infection. J. Infect. Dis. 202, S270-S277.
8. CONSTANTINE N.T., SAVILLE R.D., DAX E.M. (2005). Retroviral testing and quality assurance. MedMira Laboratories, Halifax, Nova Scotia, Canada 1-701.
9. D'ARMINIO MONFORTE A., COZZI-LEPRI A., GIRARDI E., CASTAGNA A., MUSSINI C., DI GIAMBENEDETTO S., GALLI M., CASSOLA G., VULLO V., QUIROS-ROLDAN E., LO CAPUTO S., ANTINORI A; ICONA FOUNDATION STUDY GROUP. (2011). Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir. Ther. 16, 1103-1112.
10. DASKALAKIS D. (2011). HIV diagnostic testing: evolving technology and testing strategies. Top. Antivir. Med. 19, 18-22.
11. HEFFELFINGER J.D., SULLIVAN P.S., BRANSON B.M., MASTRO T.D., PURCELL D.W., GRIFFITHS S.D., ROMAGUERA R.A., JANSSEN R.S., HILL A. (2006). Progression to AIDS and death in the era of HAART. AIDS 20, 1067-1068.
12. HEFFELFINGER J.D., SULLIVAN P.S., BRANSON B.M., MASTRO T.D., PURCELL D.W., GRIFFITHS S.D., ROMAGUERA R.A., JANSSEN R.S. (2008). Advancing HIV prevention demonstration projects: new strategies for a changing epidemic. Public. Health. Rep. 123, 5-15.
13. KRENTZ H.B., AULD M.C., GILL M.J. (2004). The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV. Med. 5, 93-98. (Pubitemid 38404662)
14. LAZZAROTTO T., GALLI C., PULVIRENTI R., RESCALDANI R., VEZZO R., LA GIOIA A., MARTINELLI C., LA ROCCA S., AGRESTI G., GRILLNER L., NORDIN M., VAN RANST M., COMBS B., MAINE G.T., LANDINI M.P. (2001). Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay. Clin. Diagn. Lab. Immunol. 8, 196-198. (Pubitemid 32065677)
15. LIKATAVICIUS G., VAN DE LAAR MJ. (2011). HIV infection and AIDS in the European Union and European Economic Area, 2010. Euro. Surveill. 16, 20030.
16. MAMMONE A., PEZZOTTI P., ANGELETTI C., ORCHI N., CARBONI A., NAVARRA A., SCIARRONE M.R., SIAS C., PURO V., GUASTICCHI G., IPPOLITO G., BORGIA P., GIRARDI E; SENDIH STUDY GROUP. (2012). HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect. Dis. 20, 12-65.
17. MASCIOTRA S., MCDOUGAL J.S., FELDMAN J., SPRINKLE P., WESOLOWSKI L., OWEN S.M. (2001). Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J. Clin. Virol. 52, S17-S22.
18. MUBAREKA S., RICHARDS H., GRAY M., TIPPLES G.A. (2007). Evaluation of commercial rubella immunoglobulin g avidity assays. J. Clin. Microbiol. 45, 231-233. (Pubitemid 46106433)
19. MYLONAKIS E., PALIOU M., LALLY M., FLANINGAN T.P., RICH J.D. (2000). Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches Am. J. Med. 109, 568-576.
20. O'BRIEN T.R., GEORGE J.R., EPSTEIN J.S., SCHOCHETMAN G. (1992). Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR Recommend Rep. 41, 1-9.
21. RE M.C., SCHIAVONE P., BON I., VITONE F., DE CRIGNIS E., BIAGETTI C., GIBELLINI D. (2008). Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. New Microbiol. 31, 19-26. (Pubitemid 351422069)
22. RE M.C., SCHIAVONE P., BON I., VITONE F., DE CRIGNIS E., BIAGETTI C., GIBELLINI D. (2010). Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. Int. J. Infect. Dis. 14, 1008-1012.
23. SELLERI M., ORCHI N., ZANIRATTI M.S., BELLAGAMBA R., CORPOLONGO A., ANGELETTI C., IPPOLITO G., CAPOBIANCHI M.R., GIRARDI E. (2007). Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies J. Acquir. Immune Defic. Syndr. 46, 145-150. (Pubitemid 47482609)
24. SULIGOI B., GALLI C., MASSI M., DI SORA F., SCIANDRA M., PEZZOTTI P., RECCHIA O., MONTELLA F., SINICCO A., REZZA G. (2002). Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J. Clin. Microbiol. 40, 4015-4020. (Pubitemid 35285783)
25. SULIGOI B., MASSI M., GALLI C., SCIANDRA M., DI SORA F., PEZZOTTI P., RECCHIA O., MONTELLA F., SINICCO A., REZZA G. (2003). Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J. Acquir. Immune Defic. Syndr. 32, 424-428. (Pubitemid 36363157)
26. SULIGOI B., RODELLA A., RAIMONDO M., REGINE V., TERLENGHI L., MANCA N., CASARI S., CAMONI L., SALFA MC., GALLI C. (2011). Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J. Clin. Microbiol. 49, 2610-2613.
27. SWEETING M.J., DE ANGELIS D., PARRY J., SULIGOI B. (2010). Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods. Stat. Med. 30, 194-202.
28. THOMAS H.I., WILSON S., O'TOOLE C.M., LISTER C.M., SAEED A.M. (1996) Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin. Exp. Immunol. 103, 185-191. (Pubitemid 26046589)
29. WATERS L., SABIN C.A. (2011) Late HIV presentation: epidemiology, clinical implications and management. Expert. Rev. Anti. Infect. Ther. 9, 877-889.
30. WILSON K.M., DI CAMILLO C., DOUGHTY L., DAX E.M. (2006). Humoral immune response to primary rubella virus infection. Clin. Vaccine Immunol. 13, 380-386.